

# United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

<https://marketpublishers.com/r/U9E92235982PEN.html>

Date: October 2017

Pages: 109

Price: US\$ 3,800.00 (Single User License)

ID: U9E92235982PEN

## Abstracts

In this report, the United States Benign Prostatic Hyperplasia (BPH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs in these regions, from 2012 to 2022 (forecast).

United States Benign Prostatic Hyperplasia (BPH) Drugs market competition by top manufacturers/players, with Benign Prostatic Hyperplasia (BPH) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top

players including

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Advaxis

Agennix

ANI Pharmaceuticals

BHR Pharma

Bristol-Myers Squibb

Boehringer Ingelheim

Dendreo

Endo Pharmaceuticals

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

Alpha-blocker

Phosphodiesterase type-5 inhibitors

5-alpha-Reductase inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for each application, including

Clinical medicine

Scientific research

Others

## Contents

United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

### **1 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS OVERVIEW**

- 1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
- 1.2 Classification of Benign Prostatic Hyperplasia (BPH) Drugs by Product Category
  - 1.2.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  - 1.2.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  - 1.2.3 Alpha-blocker
  - 1.2.4 Phosphodiesterase type-5 inhibitors
  - 1.2.5 5-alpha-Reductase inhibitors
- 1.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Market by Application/End Users
  - 1.3.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  - 1.3.2 Clinical medicine
  - 1.3.3 Scientific research
  - 1.3.4 Others
- 1.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Market by Region
  - 1.4.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Value) Comparison by Region (2012-2022)
  - 1.4.2 The West Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  - 1.4.3 Southwest Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  - 1.4.4 The Middle Atlantic Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  - 1.4.5 New England Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  - 1.4.6 The South Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
  - 1.4.7 The Midwest Benign Prostatic Hyperplasia (BPH) Drugs Status and Prospect (2012-2022)
- 1.5 United States Market Size (Value and Volume) of Benign Prostatic Hyperplasia (BPH) Drugs (2012-2022)

1.5.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2022)

1.5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2022)

## **2 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS**

2.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)

2.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Share by Players/Suppliers (2012-2017)

2.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Players/Suppliers (2012-2017)

2.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends

2.4.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate

2.4.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Product Type

## **3 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)**

3.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Region (2012-2017)

3.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Region (2012-2017)

3.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Price by Region (2012-2017)

## **4 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)**

4.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (Product Category) (2012-2017)

4.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2012-2017)

4.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2012-2017)

4.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Type (2012-2017)

## **5 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)**

5.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application (2012-2017)

5.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

## **6 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA**

6.1 Astellas Pharma

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Eli Lilly

6.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 GlaxoSmithKline

6.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

6.3.2.1 Product A

#### 6.3.2.2 Product B

6.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.3.4 Main Business/Business Overview

### 6.4 Sanofi

6.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

#### 6.4.2.1 Product A

#### 6.4.2.2 Product B

6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.4.4 Main Business/Business Overview

### 6.5 ADC Therapeutics

6.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

#### 6.5.2.1 Product A

#### 6.5.2.2 Product B

6.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.5.4 Main Business/Business Overview

### 6.6 Advaxis

6.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

#### 6.6.2.1 Product A

#### 6.6.2.2 Product B

6.6.3 Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.6.4 Main Business/Business Overview

### 6.7 Agennix

6.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

#### 6.7.2.1 Product A

#### 6.7.2.2 Product B

6.7.3 Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

#### 6.7.4 Main Business/Business Overview

### 6.8 ANI Pharmaceuticals

6.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

6.9 BHR Pharma

6.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

6.10 Bristol-Myers Squibb

6.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Category, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.10.4 Main Business/Business Overview

6.11 Boehringer Ingelheim

6.12 Dendreo

6.13 Endo Pharmaceuticals

## **7 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MANUFACTURING COST ANALYSIS**

7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs



## **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

- 8.1 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
- 8.2 Upstream Raw Materials Sourcing
- 8.3 Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturers in 2016
- 8.4 Downstream Buyers

## **9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

- 9.1 Marketing Channel
  - 9.1.1 Direct Marketing
  - 9.1.2 Indirect Marketing
  - 9.1.3 Marketing Channel Development Trend
- 9.2 Market Positioning
  - 9.2.1 Pricing Strategy
  - 9.2.2 Brand Strategy
  - 9.2.3 Target Client
- 9.3 Distributors/Traders List

## **10 MARKET EFFECT FACTORS ANALYSIS**

- 10.1 Technology Progress/Risk
  - 10.1.1 Substitutes Threat
  - 10.1.2 Technology Progress in Related Industry
- 10.2 Consumer Needs/Customer Preference Change
- 10.3 Economic/Political Environmental Change

## **11 UNITED STATES BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)**

- 11.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue Forecast (2017-2022)
- 11.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast by Type (2017-2022)
- 11.3 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast by Application (2017-2022)
- 11.4 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Forecast by Region (2017-2022)

## **12 RESEARCH FINDINGS AND CONCLUSION**

## **13 APPENDIX**

### 13.1 Methodology/Research Approach

#### 13.1.1 Research Programs/Design

#### 13.1.2 Market Size Estimation

#### 13.1.3 Market Breakdown and Data Triangulation

### 13.2 Data Source

#### 13.2.1 Secondary Sources

#### 13.2.2 Primary Sources

### 13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

## List Of Tables

### LIST OF TABLES AND FIGURES

- Figure Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
- Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (MT) by Type (2012-2022)
- Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
- Figure Alpha-blocker Product Picture
- Figure Phosphodiesterase type-5 inhibitors Product Picture
- Figure 5-alpha-Reductase inhibitors Product Picture
- Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (MT) by Application (2012-2022)
- Figure United States Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2016
- Figure Clinical medicine Examples
- Figure Scientific research Examples
- Figure Others Examples
- Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Million USD) by Region (2012-2022)
- Figure The West Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Southwest Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure The Middle Atlantic Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure New England Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure The South of US Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure The Midwest Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2022)
- Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
- Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Sales Volume (MT) (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) of Key Players/Suppliers (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players/Suppliers (2012-2017)

Figure 2016 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players/Suppliers

Figure 2017 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players/Suppliers

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players/Suppliers (2012-2017)

Figure 2016 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players/Suppliers

Figure 2017 United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players/Suppliers

Table United States Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Kg) of Key Players/Suppliers (2012-2017)

Figure United States Market Benign Prostatic Hyperplasia (BPH) Drugs Average Price (USD/Kg) of Key Players/Suppliers in 2016

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share of Top 3 Players/Suppliers

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Benign Prostatic Hyperplasia (BPH) Drugs Product Category

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Region (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Region (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Region (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region in 2016

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD)

and Market Share by Region (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in 2016

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) by Region (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2016

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2012-2017)

Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2016

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) by Types (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Type (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Application (2012-2017)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2016

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2012-2017)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate by Application (2012-2017)

Table Astellas Pharma Basic Information List

Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table Eli Lilly Basic Information List

Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table GlaxoSmithKline Basic Information List

Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table Sanofi Basic Information List

Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table ADC Therapeutics Basic Information List



Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table Advaxis Basic Information List

Table Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table Agennix Basic Information List

Table Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table ANI Pharmaceuticals Basic Information List

Table ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table BHR Pharma Basic Information List

Table BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate

(2012-2017)

Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table Bristol-Myers Squibb Basic Information List

Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Growth Rate (2012-2017)

Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in United States (2012-2017)

Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in United States (2012-2017)

Table Boehringer Ingelheim Basic Information List

Table Dendreo Basic Information List

Table Endo Pharmaceuticals Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs

Figure Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

Figure Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis

Table Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Players/Suppliers in 2016

Table Major Buyers of Benign Prostatic Hyperplasia (BPH) Drugs

Table Distributors/Traders List

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) and Growth Rate Forecast (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) Trend Forecast (2017-2022)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Type (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Type (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) Forecast by Type in 2022



Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT)  
Forecast by Application (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT)  
Forecast by Application (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT)  
Forecast by Application in 2022

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT)  
Forecast by Region (2017-2022)

Table United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share  
Forecast by Region (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share  
Forecast by Region (2017-2022)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share  
Forecast by Region in 2022

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

## I would like to order

Product name: United States Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017

Product link: <https://marketpublishers.com/r/U9E92235982PEN.html>

Price: US\$ 3,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U9E92235982PEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970